Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 11 Apr 2018
At a glance
- Drugs APX 005M (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 15 Feb 2018 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 10 Jan 2018 Status changed from active, no longer recruiting to recruiting.
- 05 Jan 2018 Status changed from recruiting to active, no longer recruiting.